Hospital Price Markups Exposed
Maharashtra Survey Exposes Extreme Price Markups on Hospital Consumables and Devices
Anonymous
Key Points
1
The FDA said it has no authority to monitor hospital bills or regulate the prices charged by hospitals, and that it submitted the findings to the NPPA while awaiting a decision on whether and how the products could be regulated.
2
The findings could revive the shelved trade-margin-rationalisation framework, which proposed capping margins at different stages of the medical supply chain.
3
FDA inspectors examined inpatient medical devices at a sizeable number of hospitals and found wide price margins; the survey covered hospitals in the Mumbai Metropolitan Region, Pune and Chhatrapati Sambhajinagar.
4
Medical-device industry representative Rajiv Nath said, “Patients deserve fair prices, not 2,800% markups, and ethical manufacturers deserve a level playing field,” framing the proposed action as both patient protection and a measure against unfair competition.
A Maharashtra hospital survey found shockingly wide markups on medical consumables, with an IV infusion set purchased for ₹11.05 sold at ₹325—a markup of nearly 2,800%. Maharashtra FDA Commissioner Tukaram Mundhe examined inpatient products across the Mumbai region, Pune, and Chhatrapati Sambhajinagar, uncovering similar patterns: a ₹6.75 syringe marked at ₹57.20, and a ₹29.41 catheter priced at ₹310. Mundhe says patients cannot compare prices during treatment, leaving them trapped by markups set by manufacturers and distributors long before they reach hospital wards.
The findings have reignited calls to regulate medical device pricing—currently uncontrolled for non-scheduled items. The Centre asked the National Pharmaceutical Pricing Authority to investigate and report back. Medical device manufacturers support action, saying fair pricing would protect patients and create equal competition. But hospitals push back, arguing they sell products at or below legal prices and cannot be judged on wholesale costs alone.
Survey Exposes 2,800% Markups on Hospital Supplies
The Maharashtra FDA inspected inpatient consumables at dozens of hospitals and found extreme price gaps. An IV infusion set cost ₹11.05 to buy but carried a printed price of ₹325. A syringe that cost ₹6.75 was marked at ₹57.20. A urinary catheter purchased for ₹29.41 was priced at ₹310. Each item showed markups ranging from 747% to 2,841% above procurement cost. Mundhe said the problem runs deep: patients admitted for urgent care cannot negotiate or shop around.
Patients Cannot Challenge Prices During Critical Care
Tukaram Mundhe framed the issue as an information problem, not a hospital scandal. Maharashtra FDA Commissioner explained: patients in hospital beds have no way to know if a price reflects real cost or a markup set months earlier by a manufacturer. They cannot compare prices or walk away. Hospitals, he said, face no legal blame—the Maximum Retail Price is printed by manufacturers upstream. The real issue: medical devices fall outside price-control rules that govern medicines, leaving the National Pharmaceutical Pricing Authority with no clear power to cap markups.
Medical Industry Backs Price Reform, Citing Unfair Competition
The medical device industry surprisingly supports Mundhe's findings. Rajiv Nath, speaking for the Association of Indian Medical Device Industry, said: "Patients deserve fair prices, not 2,800% markups, and ethical manufacturers deserve a level playing field." Domestic manufacturers say they are forced into inflated pricing to compete against high-margin rivals for hospital contracts. Girdhar Gyani, representing private hospitals, countered that facilities sell products at or below printed prices and cannot absorb overhead costs—storage, sterility, clinical handling—into wholesale purchase prices alone.
Regulator Seeks Legal Tools to Cap Hospital Supply Markups
Mundhe has asked the Department of Pharmaceuticals and NPPA to review the findings and set margin limits between procurement price and printed MRP. The Centre requested a formal report from the NPPA, signaling federal appetite for action. A dormant trade-margin rationalisation framework—proposed years ago—could be revived to cap margins at different supply-chain levels. The NPPA currently lacks blanket authority to regulate non-scheduled medical devices without changes to its legal mandate. Fixing that gap requires legislative or regulatory reform.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
30
Articles
15
Reach
45
A
AnonymousAuthor
